GR 20263 is a new broad-spectrum injectable cephalosporin which is stable to most 8i-lactamases. Its in vitro activities were of the same order as those of cefotaxime against most gram-negative bacteria, were clearly inferior to cefotaxime against Staphylococcus aureus, but were significantly more active against Pseudomonas aeruginosa. Against the 25 strains used, GR 20263 was significantly more active than any of the other agents tested: piperacillin, azlocillin, gentamicin, amikacin, and carbenicillin. GR 20263 protected mice against experimental infections with P. aeruginosa more effectively than other f-lactam antibiotics; its general effectiveness in this test was comparable with gentamicin. Studies on human volunteers showed that it produces high, long-lasting blood levels, with much of the antibiotic being recovered in the urine. Intramuscular and intravenous injections were well tolerated by the volunteers, and there were no untoward side effects.
Although the cephalosporins have been used in clinical medicine for many years, the usefulness of the currently available members of the group is impaired by limitations such as restricted antibacterial spectrum, susceptibility to ,8-lactamases from gram-negative organisms, and metabolic degradation in the body. Compounds such as cefuroxime (4) , cefotiam (7) , and cefotaxime (1, 5) have overcome some of these problems, but further improvements were desirable. For example, cefuroxime has good resistance to ,8-lactamases from many gram-negative organisms and is stable to metabolic degradation, but its intrinsic antibacterial activity is not as high as that of cefotiam. The spectrum of cefotiam is rather restricted by a degree of susceptibility of the compound to many ,B-lactamases. Cefotaxime, with good enzyme resistance and very high intrinsic antibacterial activity, suffers from metabolic degradation which reduces its activity in the body. This report summarizes the results of studies designed to evaluate this new agent with respect to its in vitro, in vivo, and human pharnacokinetic properties.
MATERIALS AND METHODS Anmtibiotics. GR 20263 was prepared in our own laboratories and used as the monosodium salt in all experiments. Cephaloridine and piperacillin were also synthesized in our own laboratories. Cefotaxime was kindly donated by Hoechst A.G., Frankfurt. The other antibiotics used were commercially available.
Bacterial isolates. The organisms used were mainly clinical isolates, identified to species by the API system (API Laboratory Products, Farnborough, England). Some isolates have been used over a period of time because they possess stable properties of special interest. All isolates were stored in sealed vials in liquid nitrogen. These stock suspensions were used to inoculate plates of Casitone agar, which were then incubated for 18 h at 37°C. Casitone broth (10 ml) was inoculated from these plates to provide the log-phase cultures used for the minimal inhibitory concentration (MIC) tests.
MIC Toxicity testing. Toxicity tests on mice, rats, rabbits, and dogs have revealed no adverse effects; these results will be reported in detail elsewhere. In particular, no adverse effects were found on the kidney or liver in rats given repeated doses of GR 20263, even at high levels. It was therefore considered safe to proceed to studies on human volunteers.
Human volunteer studies. The monosodium salt of GR 20263 was given to 15 male volunteers aged 19 to 46 years. Nine received more than one dose of drug. Each dose-route combination was given to three volunteers; the same three had 250 and 500 mg intramuscularly (i.m.) with a 3-week interval, three had 250 mg intravenously (i.v.) and 750 mg i.m. with a 3-week interval, and three received 500 mg i.v. on 2 consecutive days, with 1 g of probenecid by mouth on day 2. Physical examination and laboratory tests before each study were undertaken to exclude volunteers with abnormalities, those with positive prick tests to common allergens, and those with a history of antibiotic allergy. The studies were approved by an ethical committee, and written informed consent was obtained from each volunteer.
Sterile filtered aqueous solutions of drug were prepared immediately before use, and the dose administered was calculated as the free acid. Injections i.m. were given deep into the lateral aspect of the right thigh in 1, 2, 3, and 4 ml for the 125-, 250-, 500-, and 750-mg doses, respectively. All i.v. injections were given as a bolus over 1 min in 10 ml of aqueous solution.
Blood samples throughout each study day were taken via an indwelling winged needle. Antibiotic activity in blood and urine was estimated by microbiological assay; full hematological and biochemical tests and urinalysis were performed before and on one or two occasions after each dose on each volunteer. Creatinine clearance was measured in each volunteer on the day of dosing, to enable calculation of the drugcreatinine clearance ratio.
A best-fit concentration time curve was calculated from the observed serum levels and the timed urinary recoveries from each volunteer. higher had they been tested in nutrient broth, but the activity of the compounds measured by the agar dilution test correlated well with their in vivo activity (see Table 5 ).
Resistance to f-lactamases. The rates of hydrolysis of GR 20263 and cefotaxime were calculated relative to the rate of hydrolysis of cephaloridine at the same time by the same enzyme preparation; cephaloridine hydrolysis was arbitrarily assigned a value of 100 for comparison purposes. GR 20263 had activity equivalent to gentamicin against three of the four strains of P. aeruginosa tested; it was considerably more effective than azlocillin, cefotaxime, and carbenicillin against all four. Although the in vitro activity of GR 20263 against S. aureus is not high, it protected mice challenged with three strains of S. aureus with an effectiveness equal to that of cloxacillin, but less than that of methicillin (Table 6) .
Human volunteer studies. The average serum level/time curves for the i.m. injections of GR 20263 are shown in Fig. 2A ; the i.v. serum level curves are shown in Fig. 2B . Some pharmacokinetic parameters for both dose routes are given in Table 7 . The compound gave good longlasting serum levels after i.m. injection, with a half-life of approximately 100 min. The peak serum levels increased approximnately arithmetically with increasing dose and occurred between 1 and 1.5 h after dosing. One i.m. dose of 750 mg maintained serum concentrations in excess of 8 ,Ag/ml for 6 h. Injection i.v. gave an ultimate half-life of about 1.8 h, and 500 mg maintained serum concentrations in excess of 8 ,ug/ml for 2.6 h. The areas under the serum curve did not increase proportionally to the dose. The apparent volume of distribution was of the order of 14 liters, and the renal clearance averaged 66 ml/min. The urinary recoveries ranged from 50 to 87% with no evidence of microbiologicaly active metabolites when the urines were examined by chromatography followed by bioautograph.
After probenecid, the levels were higher, but there was no effect on the rate of excretion of the drug. It therefore appears that there is little or no net tubular secretion of GR 20263, which accounts for its longer half-life of over 1.5 h. Although it appears that there were dose-related increases in ultimate half-life and volume of distribution in these preliminary experiments, each group contained only three volunteers, and the differences observed were not considered significant.
The injections were well tolerated, with only transient pain after i.m. administration, and there was no pain or local complications after i.v. dosing. Laboratory investigations on each volunteer showed no drug-related changes. DISCUSSION GR 20263 is a parenteral cephalosporin antibiotic with a broad spectrum of antibacterial activity. It has very good activity against most species of gram-negative bacteria and is highly resistant to the f8-lactamases they produce, being comparable with cefotaxime in most instances. However, the spectrophotometric method used here appeared to be insufficiently sensitive to detect small differences between the ,B-lactamase stabilities of highly enzyme-resistant compounds; for this purpose more stringent tests such as incubation for several hours with heavy cell suspensions (2) Reeves, M. J. Bywater, and R. P. Bar, 19th ICAAC, abstr. no. 881, 1979) . In contrast, GR 20263 has high enzyme stability and an insignificant inoculum effect in vitro, together with stability in the animal body; these properties would all contribute to good activity in vivo. Its performance against the gram-negative pathogens in vivo was as good as predicted from in vitro MICs.
GR 20263 is less active in vitro against staphylococci than against gram-negative organisms; produced serum levels that exceeded 16 Jg/ml for 4 h. The MICs of GR 20263 against 97% of the specially assembled mixed collection of multiply resistant isolates were 16 Lg/ml or less, and 81% of the organisms were susceptible to 2 ,ug/ ml or less. At least 90% of the isolates in a similar collection of strains of P. aerugunosa were susceptible to 4 ,ug/ml or less.
The broad antibacterial spectrum of GR 20263, coupled with its low serum binding, good pharnacokinetics in humans, and high recovery of unchanged antibiotic in urine, suggests that it should be a highly effective therapeutic agent, particularly against difficult infections. The injections were well tolerated, and toxicological examination has revealed no side effects, so that GR 20263 should provide a safe and much needed alternative to the aminoglycosides. a Results are standardized to 70 kg to allow for differences in body weight.
